Dramatic regression of mass-forming gastric IgG4-related disease with inebilizumab: a case report.
- 1Department of Medicine, University of Tennessee Health Science Center, Knoxville, USA. [email protected].
- 2Department of Medicine, University of Tennessee Health Science Center, Knoxville, USA.
- 3Department of Pathology, University of Tennessee Health Science Center, Knoxville, USA.
Abstract
Background
Gastric immunoglobulin G4-related disease (IgG4-RD) is exceedingly rare, with fewer than 50 cases reported worldwide. Its mass-forming presentation frequently mimics malignancy, leading to high rates of unnecessary surgical resection. Inebilizumab, a CD19-directed monoclonal antibody and the first FDA-approved therapy for IgG4-RD, has not previously been described in gastric IgG4-RD. We report the first case of mass-forming gastric IgG4-RD treated with inebilizumab, achieving clinical, endoscopic, and histologic remission without surgical intervention.Case presentation
A 52-year-old man with chronic hypereosinophilia, nonischemic cardiomyopathy, and multisystem inflammatory disease presented with symptomatic anemia and a 2 cm gastric antral mass identified on CT imaging. Endoscopy revealed an antral mass, highly suspicious for malignancy. Initial biopsies showed Helicobacter pylori associated chronic active gastritis without definitive malignancy. Repeat sampling after H. pylori eradication demonstrated dense transmural lymphoplasmacytic and eosinophilic infiltration with 225 IgG4⁺ plasma cells per high-power field, an IgG4/IgG ratio of 37.5%, and a markedly elevated serum IgG4 of 1,245 mg/dL, establishing the diagnosis of gastric IgG4-RD. Concurrent lung biopsy confirmed multisystem involvement. The patient was initiated on inebilizumab. Within six weeks, follow-up endoscopy demonstrated significant resolution of the gastric mass with histologic remission (IgG4/IgG ratio < 10%), and six-month follow-up revealed near-complete resolution of the gastric abnormalities.Conclusions
This case demonstrates that CD19-targeted B-cell depletion with inebilizumab can induce rapid, profound remission in gastric IgG4-RD, obviating the need for gastrectomy and chronic glucocorticoid therapy. These findings support early consideration of IgG4-RD in the differential diagnosis of mass-forming gastric lesions and highlight the transformative potential of mechanism-based therapy in this diagnostically challenging condition.
Related
- Dramatic and sustained regression of an inferior vena cava tumor thrombus in a patient with unresectable giant hepatocellular carcinoma following sequential systemic therapy: a case report and literature review
- Extensive Gastric Necrosis and Perforation Secondary to Intragastric Balloon-Related Gastric Outlet Obstruction: A Case Report
- Hemospray for Pancreatic Cancer-Related Gastric Bleeding
- Analysis of a case of immune-related pancreatitis induced by anti-PD-1 antibody therapy for gastric cancer : A case report
- M2 macrophage-derived exosomes and miR-132-3p promote gastric cancer cell aggressiveness and attenuate ferroptosis-related changes
BibTeX
@article{jadallah2026dramatic,
title = {{Dramatic regression of mass-forming gastric IgG4-related disease with inebilizumab: a case report.}},
author = {Rami Jadallah and Vikrant Singh and Nasir Notta and Anisha Dash and Abdul Wasay and Paul Eberts and Shaker Barham},
journal = {BMC gastroenterology},
year = {2026},
month = jul,
doi = {10.1186/s12876-026-05139-z},
url = {https://europepmc.org/article/MED/42907769},
note = {CC BY},
}
RIS
TY - JOUR
TI - Dramatic regression of mass-forming gastric IgG4-related disease with inebilizumab: a case report.
AU - Rami Jadallah
AU - Vikrant Singh
AU - Nasir Notta
AU - Anisha Dash
AU - Abdul Wasay
AU - Paul Eberts
AU - Shaker Barham
PY - 2026
DA - 2026/07/01
JO - BMC gastroenterology
DO - 10.1186/s12876-026-05139-z
UR - https://europepmc.org/article/MED/42907769
AB - Background Gastric immunoglobulin G4-related disease (IgG4-RD) is exceedingly rare, with fewer than 50 cases reported worldwide. Its mass-forming presentation frequently mimics malignancy, leading to high rates of unnecessary surgical resection. Inebilizumab, a CD19-directed monoclonal antibody and the first FDA-approved therapy for IgG4-RD, has not previously been described in gastric IgG4-RD. We report the first case of mass-forming gastric IgG4-RD treated with inebilizumab, achieving clinical, endoscopic, and histologic remission without surgical intervention.Case presentation A 52-year-old man with chronic hypereosinophilia, nonischemic cardiomyopathy, and multisystem inflammatory disease presented with symptomatic anemia and a 2 cm gastric antral mass identified on CT imaging. Endoscopy revealed an antral mass, highly suspicious for malignancy. Initial biopsies showed Helicobacter pylori associated chronic active gastritis without definitive malignancy. Repeat sampling after H. pylori eradication demonstrated dense transmural lymphoplasmacytic and eosinophilic infiltration with 225 IgG4⁺ plasma cells per high-power field, an IgG4/IgG ratio of 37.5%, and a markedly elevated serum IgG4 of 1,245 mg/dL, establishing the diagnosis of gastric IgG4-RD. Concurrent lung biopsy confirmed multisystem involvement. The patient was initiated on inebilizumab. Within six weeks, follow-up endoscopy demonstrated significant resolution of the gastric mass with histologic remission (IgG4/IgG ratio < 10%), and six-month follow-up revealed near-complete resolution of the gastric abnormalities.Conclusions This case demonstrates that CD19-targeted B-cell depletion with inebilizumab can induce rapid, profound remission in gastric IgG4-RD, obviating the need for gastrectomy and chronic glucocorticoid therapy. These findings support early consideration of IgG4-RD in the differential diagnosis of mass-forming gastric lesions and highlight the transformative potential of mechanism-based therapy in this diagnostically challenging condition.
SN - 1471-230X
ER -